Moderna will enter more than 20,000 million euros in 2022 for its vaccine against Covid-19

Approves a 2,955 million share repurchase program

Aug. 3 () –

The Moderna biotechnology company hopes to enter around 21,000 million dollars (20,690 million euros) this year thanks to the agreements signed for the early sale of its vaccine against Covid-19, according to the company, which reduced its production by 21%. net profit in the second quarter, up to 2,197 million dollars (2,149 million euros).

These contracts include the announced agreement with the United States Government for 70 million doses (the option has been exercised for 4 million pediatric doses) and an adjustment for the doses that remain unassigned by Covax due to the lack of demand.

Moderna forecasts that second-half sales “will be higher in the fourth quarter than in the third, driven by the updated vaccine approval schedule and a corresponding increase in new product manufacturing.”

“We continue to have advance purchase agreements for expected delivery in 2022 of some $21 billion of sales,” Moderna CEO Stéphane Bancel said in a statement.

At the end of the second quarter, the laboratory obtained a net profit of 2,197 million dollars (2,149 million euros), 21% below the result recorded in the same period of 2021, while revenues between April and June totaled 4,749 million dollars (4,646 million euros), 9% more.

In this way, in the first half of the year, Moderna obtained a net profit of 5,854 million dollars (5,727 million euros), 46.3% more than a year before, while revenues reached 10,815 million dollars (10,581 million euros), 71.9% more.

Likewise, the company has advanced that, due to its “solid financial position and commercial momentum”, the board of directors has approved a new share repurchase program worth 3,000 million dollars (2,955 million euros).

“Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in new drug research, a strong balance sheet of $18 billion of cash and a nimble, mission-driven team of over 3,400 people and growing. We will continue to invest and grow as we have never been more optimistic about Moderna’s future.”

Moderna currently has four infectious disease vaccines in phase 3 trials, and is expecting “significant data” from proof-of-concept studies in rare diseases and immuno-oncology later this year.

“Our teams are actively working to prepare for the launch of these new products to help patients and drive growth. This is an exciting time for Moderna as we continue to see significant scientific and commercial momentum.”